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Abstract
Simon’s two-stage designs are frequently used in phase II single-arm trials for ecacy studies. A concern of
safety studies is too many patients who experience an adverse event. We show that Simon’s two-stage designs
for ecacy studies can be similarly used to design a two-stage safety study by modifying some of the design
parameters. Given the type I and II error rates and the proportion of adverse events experienced in the first
stage cohort, we prescribe a procedure whether to terminate the trial or proceed with a stage 2 trial by recruiting
additional patients. We study the relationship between a two-stage design with a safety endpoint and an ecacy
endpoint as well as use simulation studies to ascertain their properties. We provide a real-life application and a
free R package gen2stage to facilitate direct use of two-stage designs in a safety study.
Keywords: safety, single-stage design, tolerability, toxicity, two-stage design
1. Introduction
Phase II single-arm two-stage designs are typically used to determine if a drug is suciently eca-
cious to move on a randomized phase III trial. Sometimes, we would like to design a trial to examine
whether the drug is safe due to a significant adverse event or toxicity. These are often called toxicity
or tolerability studies instead of safety studies and they occur frequently. Results from a sample of
subjects are then compared to an adverse event rate from historical controls. If the drug appears to
have a fewer number of patients with a toxic response than expected, the trial proceeds to stage 2 for
further research; otherwise, the study terminates at stage 1.
Drug trials estimate the true success rate p of a drug. These are ecacy studies and are conducted
in one stage or two stages. In Simon’s two-stage ecacy studies (Simon, 1989), a minimal ecacy
response rate p0 is pre-specified in the null hypothesis versus a user-specified higher rate p1 in the
alternative hypothesis. Given type I and II error rates, there are four variables to optimize the design
problem: the patient number n1 to recruit in stage 1, the total number of patients n required in the
entire trial, the rejection number r1 in stage 1 and the cumulative rejection number r in the entire trial.
If the estimated response rate is smaller than p0, the treatment is deemed not ecacious and the trial
stops in the first stage. Otherwise, it proceeds to the second stage, where the number of additional
patients and the number of additional responders have to be determined to arrive at a decision for the
trial.
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These optimization problems are typically solved by a greedy search over the set of constrained
positive integers (Kim and Wong, 2017). There are two optimality criteria for Simon’s two-stage
designs: a minimax criterion that minimizes the maximum sample size and an optimal design that
minimizes the expected sample (Simon, 1989). Since Simon’s landmark paper was proposed, many
variations of the strategies have been proposed for phase II designs. Green and Dahlberg (1992) in-
vestigated a two-stage design for multicenter trials when the attained sample size is not the planned
one. Mander and Thompson (2010) and Mander et al. (2012) proposed novel designs that are op-
timal under the alternative hypothesis. Wason et al. (2011) proposed reducing the sample size for
phase II trials with a continuous outcome, and Kwak and Jung (2014) considered a two-stage adaptive
optimal design for single arm trials with right-censored survival time. Ensign et al. (1994), Chen
(1997), and Chen and Shan (2007) proposed phase II designs with three stages. Under the Bayesian
framework, Thall and Simon (1994) proposed posterior probability to account for uncertainty re-
garding the response rates of the null and alternative hypotheses. Lee and Liu (2008) developed an
ecient and flexible design using Bayesian predictive probability and the minimax criterion. Cai et
al. (2014) constructed a phase II trial design for continuous monitoring when delayed responses are
present using multiple imputation. Zhou et al. (2017) recently proposed a flexible Bayesian optimal
phase II (BOP2) design to handle simple and complex endpoints such as binary, ordinal, nested, and
co-primary endpoints.
Several phase II single-arm two-stage designs are available for toxicity studies, but those stud-
ies are designed to monitor toxicity as a secondary or a co-primary endpoint to determine if a drug
or treatment is ecacious; see, Bryant and Day (1995), Conaway and Petroni (1996), Ray and Rai
(2011), and references. Therefore, those designs are not directly applicable for safety studies where
the primary endpoint is the proportion of adverse events or toxicity. The motivation for this work is
that there are no phase II single-arm safety studies that utilize Simon’s two-stage designs. There are
two possible reasons for this: (i) there are allusions that this is possible but the theoretical justifica-
tions have not been worked out, and (ii) there is no software package to generate a two-stage design
for a safety study. PASS 15 (NCSS, LLC), a widely used power and sample size calculation com-
mercial software package, has an option for Simon’s two-stage designs under the ‘Proportions: One
Proportion: Group-Sequential: Two-Stage Phase II Clinical Trials’ category, but cannot handle safety
cases where a null proportion p0 is larger than an alternative proportion p1 (i.e., p0 > p1). Similarly,
STATA 15.0 (StataCorp, LLC) and nQuery 8.0 (StatSols, Ltd.) only have a code to generate a Simon’s
two-stage design for an ecacy trial but not for a safety trial.
As an example of a safety study, Rugo et al. (2017) used a one-sample proportion test to estimate
the required sample size for a phase II single-arm study to assess the incidence of grade 2 or worse
everolimus-related stomatitis in women when dexamethasone mouthwash (SWISH) is used. On the
basis of historical controls, the incidence rate of grade 2 or worse stomatitis without SWISH was
considered to be 0.33 (i.e., the null hypothesis is p0 = 0:33). The alternative hypothesis is that the
use of SWISH would lead to an absolute reduction of 0.13 (i.e., p1 = 0:20). A direct calculation
shows that the estimated required sample size was 73 for a one-sided 5% sized test with 80% power
using a one-sample proportion test. If two-stage designs are applied to this trial using our proposed
approaches, the estimated sample sizes are (r1; n1; r; n) = (18; 26; 63; 85) and (50; 67; 54; 72) for the
optimal and minimax designs, respectively. Therefore, they could have an opportunity to evaluate the
study early at the end of the first stage using either minimax or optimal designs that could also save
3 patients compared to their original design if the minimax design was employed. We provide details
on how to apply a two-stage design to this SWISH trial in Section 3.2.
We now develop a theory to construct a two-stage safety trial following Simon’s original two-
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stage design. In particular, we provide analytical formulas parallel to those for an ecacy study and
show how a two-stage safety study can be found directly from Simon’s two-stage design. We also
compare single-stage and two-stage designs for safety studies through simulation studies and apply
our results to construct a phase II two-stage design for a real application (Rugo et al., 2017). The user
can implement our phase II single- and two-stage designs for a single-arm trial using our R package
called gen2stage available at http://cansur.wayne.edu/.
2. Designs for one and two-stage safety studies
Throughout, let b(x; n; p) and B(x; n; p) be the probability mass function (pmf) and the cumulative
distribution function (cdf), respectively, of a random variable X that follows the binomial distribution
with parameters n and p, i.e., X  Binom(n; p). We now describe the theoretical relationships between
designs for safety studies and those for ecacy studies.
2.1. Single-stage design
A single-stage design is estimated using Fleming’s single-stage procedure with the exact binomial
distribution (Fleming, 1982; A’Hern, 2001). The true rate (or proportion) is denoted by p. The
standard rate is assumed to be p0 under the null hypothesis (i.e., H0 : p = p0) and the new treatment
can use further research if the null hypothesis is rejected in favor of the alternative hypothesis, where
the rate is p1 (i.e., H1 : p = p1). For a safety study, the toxicity (or adverse event) rate is the primary
endpoint. We wish to test the toxicity rate is p0, which is the maximum allowed; consequently, we
reject the null hypothesis and terminate the study if there are too many toxic responses among the
first cohort of patients. In the alternative hypothesis, the target toxicity rate is p1 with p0 > p1. Then
the single-stage design aims to find a good design by testing H0 : p = p0 vs. H1 : p = p1 with
predetermined p0, p1, type I error rate  and type II error rate , respectively. The single-stage design
for the ecacy or safety studies is performed as:
1. Begin by recruiting n patients of the single-arm phase II design and observe the number of the
responses or toxicity, x, out of n patients.
2. When p0 < p1 (for ecacy), the null hypothesis is H0 : p = p0 and the alternative hypothesis
H1 : p = p1 with p1 > p0. The decision rule is to fail to reject the null hypothesis H0 if the total
number x of responses is less than r (i.e., x  r).
3. When p0 > p1 (for safety), the null hypothesis is H0 : p = p0 and the alternative hypothesis
H1 : p = p1 with p1 < p0. The decision rule is to fail to reject the null hypothesis H0 if the total
number x of subjects experiencing toxicity is larger than r (i.e., x  r).
The single-stage design has two parameters  = (r; n) to be optimized. Given error rates  and ,
their optimal values are found by a greedy search. If the true rate is p, the probability of failing to
reject H0 is given by (
P1(jp) = B(r; n; p); if p0 < p1;
S 1(jp) = 1   B(r   1; n; p); if p0 > p1; (2.1)
where B is the cdf of a binomial distribution with parameters n and p. Note that we hereafter use
the subscripts of 1 and 2 to indicate the probability of failing to reject H0 for the single-stage and the
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two-stage designs, respectively. To find an appropriate design, we first identify a set e that contains
all  that satisfies the two user-specified error constraints:(
P1(jp0)  1   ; P1(jp1)  ; if p0 < p1;
S 1(jp0)  1   ; S 1(jp1)  ; if p0 > p1: (2.2)
The optimal choice of ˆ in emay be determined by the following optimality criterion for both ecacy
and safety cases:
ˆ = argmin
2e n; (2.3)
where n is the required sample size corresponding to  = (r; n).
2.2. Two-stage design
The two-stage design evaluates the trial endpoint at each stage and allows the trial to proceed to the
second stage only if one rejects the null hypothesis at the end of the first stage. The required sample
sizes for the first and second stages are denoted by n1 and n2, respectively, where the total required
sample size n = n1 + n2. Using similar notation used in the single-stage design, the two-stage design
for ecacy or toxicity tests H0 : p = p0 versus H1 : p = p1 with p0 < p1 or H1 : p = p1 with p1 < p0,
respectively, as:
 Step I: Begin by recruiting n1 patients in the first stage of the trial and observe the number of the
responses or toxicity, x, out of n1 patients.
 Step II:
1. When p0 < p1 (for ecacy), if x  r1, stop the trial and fail to reject H0 (i.e., p  p0); if x > r1,
power the study at (1   ) for p = p1 and enter n2 = n   n1 additional patients into the study.
Reject the alternative hypothesis H1 (i.e., p  p1) if the total number of responses  r out of n
patients.
2. When p0 > p1 (for safety), if x  r1, stop the trial and fail to reject H0 (i.e., p  p0); if x < r1,
power the study at (1   ) for p = p1 and enter n2 = n   n1 additional patients into the study.
Reject the alternative hypothesis H1 (i.e., p  p1) if the total number of toxicity  r out of n
patients.
The two-stage designs for ecacy or safety have four parameters  = (r1; n1; r; n) to optimize
given error rate constraints. The probability of failing to reject H0 when the true rate is p is given by8>>>>>>>>><>>>>>>>>>:
P2(jp) = B(r1; n1; p) +
min(n1;r)X
x=r1+1
b(x; n1; p)B(r   x; n2; p); if p0 < p1;
S 2(jp) = 1   B(r1   1; n1; p) +
max(0;r n2)X
x=r1 1
b(x; n1; p)(1   B(r   x   1; n2; p)); if p0 > p1;
(2.4)
where b and B are the pmf and cdf of a binomial distribution with n = n1 + n2. Furthermore, the
probability of early termination (PET) at the end of the first stage is
PET(pj) =
(
PETP(pj) = B(r1; n1; p); if p0 < p1;
PETS (pj) = 1   B(r1   1; n1; p); if p0 > p1; (2.5)
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where the subscripts P and S hereafter indicate the designs for testing H0 : p = p0 versus H1 : p = p1
with p0 < p1 for ecacy and designs for testing H0 : p = p0 versus H1 : p = p1 with p0 > p1 for
safety, respectively. The expected sample size with p as the response probability is then
E(Njp; ) =
(
EP(Njp; ) = n1 + (1   B(r1; n1; p))n2; if p0 < p1;
ES (Njp; ) = n1 + B(r1   1; n1; p)n2; if p0 > p1: (2.6)
The sought two-stage design for evaluating toxicity is to find a design ˆ 2 e, where e contains all 
that satisfies two natural error constraints:(
P2(jp0)  1   ; P2(jp1)  ; if p0 < p1;
S 2(jp0)  1   ; S 2(jp1)  ; if p0 > p1: (2.7)
The goodness of ˆ may be determined by one of the following two optimality criteria:
Optimal: ˆ = argmin
2e E(N jp0; ); (2.8)
Minimax: ˆ = argmin
2e n; (2.9)
where n is the required sample size corresponding to  = (r1; n1; r; n).
2.3. Theoretical results
We describe several relationships between the designs for ecacy, p0 < p1, and those for safety,
p0 > p1. These relationships enable us to find one or two stage optimal designs for toxicity studies for
testing p = p0(> p1) versus H1 : p = p1 from optimal designs for ecacy studies to test p = p0(< p1)
versus H1 : p = p1. Suppose a random variable X follows the binomial distribution with parameters
n and p, i.e., X  Binom(n; p). An important result which we will use repeatedly and without further
mention is b(x; n; p) = b(n   x; n; 1   p), where x; n 2 N, x  n, and p 2 [0; 1].
We now discuss several useful relationships between decision rules to test toxicity and ecacy
rates with justifications.
Theorem 1. Consider a single-stage design with  = (r; n). Then P1(jp) = S 1(j1   p), where
 = (n   r; n).
Proof:
P1(jp) = B(r; n; p) (by Equation (2.1))
=
rX
x=0
b(n   x; n; 1   p)
=
n rX
y=n
b(y; n; 1   p) (by substituting y for n   x)
= 1   B(n   r   1; n; 1   p)
= S 1(j1   p) (by Equation (2.1))

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Corollary 1. For a single-stage design, if ˆ = (r; n) is the optimal single-stage design for p0 < p1,
then ˆ = (n   r; n) is the optimal single-stage design for 1   p0 > 1   p1 and vice versa.
Proof: By Theorem 1, finding the set of feasible solutions ˆ that satisfies P1(jp0)  1    and
P1(jp1)   is equivalent to finding the set of feasible solutions ˆ that satisfies S 1(jp0)  1    and
S 1(jp1)  . Therefore,  = (r; n) 2 ˆ if and only if  = (n   r; n) 2 ˆ. Thus, min n = min n and
so ˆ = (n   r; n) is the optimal design for 1   p0 > 1   p1. 
Corollary 1 implies that finding the optimal single-stage design for p0 > p1 is identical to finding
the design for 1   p0 < 1   p1. A similar relationship on the probability of failing to reject H0 when
the true rate is p can be established.
Here is an example for a single-stage design for testing toxicity.
Example 1. Consider a standard therapy (historical control) whose incidence rate of adverse events
is 0.5 (i.e., p0 = 0:5) and suppose that an investigator wants to see if experimental therapy can reduce
the incidence rate of adverse events down to 0.3 (i.e., p1 = 0:3). We want to design a phase II single-
stage single-arm trial with 90% power at one-sided 10% level (i.e.,  = 0:1 and  = 0:1). Then,
by Corollary 1, it is sucient to find the optimal design, ˆ = (r; n), for 0:5 = p0 < p1 = 0:7 in
order to find the optimal single-stage design, ˆ = (n   r; n), for 0:5 = p0 > p1 = 0:3. Therefore,
ˆ = (16; 39) because ˆ = (23; 39), implying that, if 16 or more adverse events occur in the 39 patients,
the experimental therapy is rejected.
Theorem 2. Consider a two-stage design with  = (r1; n1; r; n). Then P2(jp) = S 2(j1   p), where
 = (n1   r1; n1; n   r; n).
Proof:
P2(jp) = B(r1; n1; p) +
min(n1;r)X
x=r1+1
b(x; n1; p)B(r   x; n2; p) (by Equation (2.4))
= 1   B(n1   r1   1; n1; 1   p) +
min(n1;r)X
x=r1+1
b(n1   x; n1; 1   p) 1   B(n2   r + x   1; n2; 1   p)
(by Theorem 1)
= 1   B(n1   r1   1; n1; 1   p) +
max(0;n r n2)X
y=n1 r1 1
b(y; n1; 1   p) 1   B(n   r   y   1; n2; 1   p)
(by substituting y for n1   x)
= S 2(j1   p) (by Equation (2.4)):

Using Theorem 1, calculations of the PET and the expected sample size for toxicity studies are
similar to those for ecacy studies. It can be shown that for a two-stage design with  = (r1; n1; r; n),
we have PET(pj) = PET(1   pj) and EP(N jp; ) = ES (Nj1   p; ), where PET is the probability of
early termination after the first stage and  = (n1   r1; n1; n  r; n). Therefore, on the basis of Theorem
2 and Corollary 2, two-stage designs for p0 > p1 can be estimated by finding the two-stage designs
for p0 < p1, respectively.
Phase II two-stage single-arm clinical trials for testing toxicity levels 169
Corollary 2. If ˆ = (r1; n1; r; n) is the optimal two-stage design for p0 < p1, then ˆ = (n1   r1; n1; n 
r; n) is the optimal two-stage design for 1   p0 > 1   p1 and vice versa. This relationship also holds
for the minimax two-stage design.
Proof: Since ˆ is the optimal two-stage design,
ˆ = argmax
2ˆ
EP(Njp0; ) (by Equation (2.8))
= argmax
2ˆ
fn1 +  1   B(r1; n1; p)n2g (by Equation (2.6))
= argmax
2ˆ
fn1 + B(n1   r1   1; n1; 1   p)n2g (by Theorem 1):
However, by Theorem 2, finding the set of feasible solutions ˆ that satisfies P2(jp0)  1    and
P2(jp1)   is equivalent to finding a set of feasible solutions ˆ that satisfies S 2(jp0)  1    and
S 2(jp1)  . That is,  = (r1; n1; r; n) 2 ˆ if and only if  = (n1   r1; n1; n   r; n) 2 ˆ, resulting that
max2ˆfn1 + B(n1   r1   1; n1; 1   p)n2g = max2ˆfn1 + B(n1   r1   1; n1; 1   p)n2g. Therefore, by
Equation (2.8), ˆ = argmax2ˆ ES (Nj1   p0; ), showing that ˆ = (n1   r1; n1; n   r; n) is the optimal
design for 1   p0 > 1   p1.
When ˆ is the minimax two-stage design, by Theorem 2, we have min2ˆ n =min2ˆ n; therefore,
ˆ = argmin2ˆ n by Equation (2.9), showing that ˆ = (n1   r1; n1; n   r; n) is the minimax design for
1   p0 > 1   p1 
It follows from Theorem 2 and Corollary 2. The two-stage design for testing toxicity when p0 > p1
can be obtained by finding the two-stage designs for p0 < p1 and conversely.
Here is an example of a two-stage design for testing toxicity.
Example 2. Consider the same design parameter values in Example 1 for the single-stage design,
(p0; p1; ; ) = (0:5; 0:3; 0:1; 0:1). By Corollary 2, it is sucient to find an optimal design, ˆ =
(r1; n1; r; n), for 0:5 = p0 < p1 = 0:7 in order to find an optimal two-stage design, ˆ = (n1  
r1; n1; n  r; n), for 0:5 = p0 > p1 = 0:3. The resulting optimal two-stage design is ˆ = (10; 21; 19; 45)
because ˆ = (11; 21; 26; 45) and the minimax two-stage design is ˆ = (12; 23; 16; 39) because ˆ =
(11; 23; 23; 39). The expected null sample sizes E(N jp0) for the optimal and minimax designs are
28.96 and 31, respectively. For the optimal design, this means that if 10 or more adverse events occur
among the first 21 patients at the end of stage 1, we terminate the trial for excess adverse events
and concluded that experimental therapy does not warrant further investigation. Otherwise, the trial
proceeds to stage 2 and enrolls additional 24 patients. If 19 or more of the 45 patients experience
adverse events at the end of stage 2, we conclude that the experimental therapy results in excess
adverse events not requiring further investigation. Otherwise, we consider the experimental therapy
for further investigation in subsequent trials. A similar interpretation applies for the minimax design.
3. Applications
3.1. Simulation studies
We use simulation studies to show optimal single- and two-stage designs for toxicity studies using
various design parameters where p0 > p1. Our simulation covers two sets of type I () and type
II () error rates with (; ) 2 f(0:05; 0:20); (0:10; 0:20)g and seven sets of target toxicity rates with
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Table 1: Single-stage and two-stage (optimal and minimax) designs with  = 0:05 and  = 0:2
p0 p1 r1 n1 r n E(Njp0) PET(p0) ˆ ˆ
Single 5 28 0.047 0.142
0.3 0.1 Optimal 2 6 5 27 14.82 0.58 0.049 0.196
Minimax 4 23 5 26 23.16 0.95 0.045 0.199
Single 10 36 0.045 0.168
0.4 0.2 Optimal 4 11 13 43 20.48 0.70 0.049 0.198
Minimax 5 13 10 35 20.77 0.65 0.050 0.192
Single 14 37 0.049 0.193
0.5 0.3 Optimal 7 15 17 43 23.50 0.70 0.050 0.196
Minimax 11 23 14 37 27.74 0.66 0.048 0.199
Single 20 42 0.038 0.197
0.6 0.4 Optimal 9 16 23 46 24.52 0.72 0.049 0.199
Minimax 17 34 19 39 34.44 0.91 0.049 0.198
Single 23 39 0.050 0.168
0.7 0.5 Optimal 10 15 28 46 23.63 0.72 0.050 0.197
Minimax 13 19 23 39 25.69 0.67 0.046 0.196
Single 24 35 0.034 0.195
0.8 0.6 Optimal 10 13 31 43 20.58 0.75 0.050 0.200
Minimax 14 18 23 33 22.25 0.72 0.046 0.199
Single 20 25 0.033 0.194
0.9 0.7 Optimal 9 10 24 29 15.01 0.74 0.047 0.195
Minimax 14 15 20 25 19.51 0.55 0.033 0.198
PET = probability of early termination.
0:3  p0  0:9 and p0   p1 = 0:2. The estimation procedure is the same as the original Simon’s
two-stage design (Simon, 1989).
Table 1 shows single-stage and two-stage designs when  = 0:05 and  = 0:2. We observe that
the required total sample sizes (n) of the single-stage design are larger than the minimax two-stage
design; however, the single-stage design has the smaller required total sample sizes than the optimal
two-stage design except when p0 = 0:3. As expected, the optimal two-stage design has a smaller
expected total sample size under the null hypothesis E(Njp0) than the minimax two-stage design.
Interestingly, the single-stage design has smaller estimates of  than the two-stage designs, implying
that  is underestimated under the single-stage design. Two-stage designs have advantages over single-
stage designs because they allow the early evaluation of the plausibility of the null hypothesis and can
save up to 3 patients compared to the single-stage design. It is noteworthy that the critical values, r1
and r, are the minimum number of adverse events or toxicity leading to a rejection of a null hypothesis
dierent from the ecacy designs. As an example, suppose 0:4 = p0 > p1 = 0:2 and the minimax
design is used. We then terminate the study at the end of stage 1 if 5 or more toxicities occur out
of 13 patients for excess toxicities. Otherwise, the study proceeds to the second stage and enrolls
additional 22 patients. If 10 or more toxicities occur out of 35 patients at the end of the second stage,
we conclude that the experimental therapy has excess toxicities. Otherwise, the experimental therapy
is considered for further investigation in subsequent trials.
Table 2 displays the simulated single-stage and two-stage designs when  = 0:10 and  = 0:2.
Similarly, as observed when  = 0:05 in Table 1, the required total sample sizes (n) for the minimax
two-stage designs are always smaller than the single-stage designs. However, the optimal two-stage
designs require the same or larger total sample sizes than single-stage designs except when p0 = 0:3.
One interesting case is when p0 = 0:9 and all designs have the same required total sample size
(n = 18) and the same rejection boundary (r = 15). Moreover, the rejection boundary (r1 = 7) and the
required sample size (n1 = 7) at stage 1 are the same across the two two-stage designs, meaning that,
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Table 2: Single-stage and two-stage (optimal and minimax) designs with  = 0:10 and  = 0:2
p0 p1 r1 n1 r n E(Njp0) PET(p0) ˆ ˆ
Single 4 21 0.086 0.152
0.3 0.1 Optimal 2 6 4 20 11.88 0.58 0.090 0.194
Minimax 3 15 4 19 15.51 0.87 0.092 0.199
Single 7 24 0.096 0.189
0.4 0.2 Optimal 4 11 10 31 16.93 0.70 0.100 0.192
Minimax 5 11 7 24 17.93 0.47 0.093 0.199
Single 11 28 0.092 0.191
0.5 0.3 Optimal 6 12 13 32 19.74 0.61 0.090 0.195
Minimax 8 15 11 28 21.50 0.50 0.090 0.199
Single 15 30 0.097 0.175
0.6 0.4 Optimal 7 12 20 38 20.70 0.67 0.098 0.195
Minimax 10 16 14 28 21.67 0.53 0.099 0.197
Single 18 30 0.084 0.181
0.7 0.5 Optimal 10 15 20 32 19.73 0.72 0.100 0.196
Minimax 9 12 17 28 20.12 0.49 0.095 0.198
Single 17 24 0.089 0.192
0.8 0.6 Optimal 10 12 18 25 17.74 0.56 0.099 0.185
Minimax 12 14 17 24 19.52 0.45 0.087 0.198
Single 15 18 0.098 0.165
0.9 0.7 Optimal 7 7 15 18 12.74 0.48 0.089 0.200
Minimax 7 7 15 18 12.74 0.48 0.089 0.200
PET = probability of early termination.
if all 7 patients experience toxicities at the end of the first stage, we terminate the study for excessive
toxicities.
3.2. Stomatitis study
We revisit the stomatitis study conducted by Rugo et al. (2017). The purpose of that study was
to assess the incidence of grade 2 or worse everolimus-related stomatitis in women who used dex-
amethasone mouthwash (SWISH). The study assumed that the incidence rate of grade 2 or worse
stomatitis without SWISH was 0.33 (i.e., p0 = 0:33) based on historical controls and then proposed
that the use of SWISH would lead to an absolute reduction of 0.13 (i.e., p1 = 0:20). We now use
Corollaries 1 and 2 to construct a single-stage design and a two-stage design under the hypotheses
that 0:67 = 1   0:33 = p0 < p1 = 1   0:20 = 0:80 for specified type I and II error rates.
Suppose  = 0:05 and  = 0:20. Since the optimal exact single-stage design with 0:67 = p0 <
p1 = 0:80 is (r; n) = (55; 73), the optimal exact single-stage design with 0:33 = p0 > p1 = 0:20
becomes (r; n) = (18; 73) and the estimated ˆ = 0:047 and ˆ = 0:196. By Corollary 1, The minimax
and optimal two-stage designs with 0:67 = p0 < p1 = 0:80 are (r1; n1; r; n) = (50; 67; 54; 72) and
(18; 26; 63; 85), respectively. It follows that, by Corollary 2, the minimax and optimal two-stage
designs with 0:33 = p0 > p1 = 0:20 become (r1; n1; r; n) = (50; 67; 54; 72) and (18; 26; 63; 85),
respectively. The estimated ˆ and ˆ are 0.049 and 0.200 for the minimax design and 0.050 and 0.196
for the optimal design. Compared to the single-stage design, the two-stage designs have the flexibility
to stop the trial early when there is evidence of excess adverse events. Consequently, patients can
benefit from the two-stage designs by not having them exposed unnecessarily to treatments with undue
adverse events. Therefore, employing the optimal two-stage design can assess the incidence of adverse
events early as a form of an interim analysis at the end of stage 1 and protect patients. For example, if
18 patients experienced grade 2 or worse everolimus-related stomatitis out of 26 patients at the end of
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stage 1, we can terminate the study for excessive adverse events and do not have to wait till the trial
concludes.
4. Discussion
The primary objective of a phase II single-arm study is often to assess safety and/or tolerability of a
certain drug or treatment by the incidence of adverse events or toxicity. A phase II single-arm safety
study aims to show that the rate of an adverse event is lower in the experimental therapy than that in
the historical control (i.e., p0 > p1). In contrast, a phase II single-arm ecacy study aims to show
that the rate of having a responder is higher in experimental therapy than in the historical control (i.e.,
p0 < p1). This is one of the major dierences between safety and ecacy studies.
Two-stage designs are widely used in phase II single-arm ecacy studies because of the flexibility
to stop early due to futility and avoid the unnecessary exposure of patients to ineective therapies.
However, there appears to be no phase II single-arm safety studies that employ two-stage designs.
This means that current safety studies have no opportunity to stop a trial early due to futility. One
possible explanation may be a lack of theoretical justification and dedicated software. Our work
shows that the traditional Simon’s two-stage designs to evaluate ecacy in a single one-arm trial can
also be used for a one or two-stage safety trial with p0 > p1. We presented their analytical formulas
and established relationships between the two types of designs and investigators can now easily find
single-stage or two-stage designs for a safety study using available designs for an ecacy study.
Jung et al. (2001) proposed a graphical approach to find a suboptimal two-stage design that is
a trade-o between optimal and the minimax designs. This approach graphically searches for the
suboptimal design solely based on the required total sample size (n) and the expected null sample
size E(Njp0). It is not dicult to observe that Corollary 2 shows that optimal and minimax two-stage
designs for safety hold for the same n and E(N jp0) as those for ecacy, implying that Corollary 2 is
valid for suboptimal two-stage designs for safety and ecacy. Therefore, the graphical approach can
be applied to find two-stage safety designs to find a suboptimal two-stage design.
It is noteworthy that the Bayesian optimal phase II (BOP2) design (Zhou et al., 2017) can monitor
the toxicity endpoint through the binary toxicity endpoint at http://www.trialdesign.org/. However,
in order to implement the BOP2 design, a user needs to provide preselected sample sizes for the
first and second stages, while the proposed approach requires a desirable power. The BOP2 design
computes the achieved power based on fixed sample sizes (i.e., a post-hoc power calculation), while
our proposed approach is to estimate the sample sizes based on a pre-specified power (i.e., the prior
sample size estimation).
To facilitate practitioners to use our single-stage and two-stage designs for a phase II single-
arm study, including Jung et al.’s graphical approaches, we implement our computer codes in an R
package gen2stage. Using the gen2stage package, investigators can generate single-stage or two-
stage designs for an ecacy study or a toxicity study whether we are concerned with p0 < p1 or
p0 > p1.
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